Categories
I-CARE Early Covid (187)
I-CARE Flu and RSV (36)
I-PREVENT (153)
I-RECOVER Long Covid (111)
I-RECOVER Post-Vaccine (320)
MATH+ (171)
Tags
ACE2 protein (10)
acute respiratory distress syndrome (13)
Alopecia (7)
Anti-inflammatory (8)
Antidepressants (9)
Ascorbic Acid (9)
autoantibodies (10)
autophagy (24)
Calcifediol (6)
Cancer (9)
Corticosteroids (8)
COVID-19 (255)
COVID-19 Vaccines (8)
Curcumin (8)
Cytokines (10)
Depression (10)
Famotidine (14)
flavonoids (5)
Glucocorticoids (6)
Hydroxychloroquine (12)
Hyperbaric Oxygen Therapy (9)
Inflammation (14)
ivermectin (46)
long COVID (21)
Mast Cells (8)
Melatonin (20)
molnupiravir (5)
N-Acetylcysteine (6)
Non-Invasive Brain Stimulation (8)
Omicron (7)
Oxytocin (8)
Pneumonia (8)
quercetin (15)
resveratrol (5)
SARS-CoV-2 (72)
SARS-CoV-2 mRNA Vaccines (7)
Sepsis (15)
spermidine (11)
Spike Protein (10)
Thrombosis (9)
Tinnitus (12)
Valproic Acid (5)
Vitamin C (16)
Vitamin D (9)
Zinc (12)
Authors: Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP PMID: 35294537 PMCID: PMC8928006 DOI: 10.1001/jamanetworkopen.2022.2735 Abstract Importance: SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed. [...]
Categories: I-CARE Early Covid
